Aescap Venture et al. back Orphazyme

Existing investors Novo A/S and Sunstone Capital also participated in the investment round. The investors were convinced by the potental broad application of Orphazyme's products. Aescap Venture invested from its €105m Aescap Fund I.

Company
Copenhagen-based Orphazyme is a biopharmaceutical company developing treatments for lysosomal storage disorders, a genetic dysfunction. The company is based on discoveries from its scientific founders professor Marja Jäättela and Dr Thomas Kirkegaard Jensen. Founded in June 2009, the business has established collaborations with academic institutions in Europe and the US.

People
Hakan Goker managed the investment for Aescap and will join the board of directors together with Kim Dueholm and Peter Moldt from Novo.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Early-stage
• Healthcare
• Denmark
• Sunstone Capital A/S